(NEO) NeoGenomics - Ratings and Ratios
Genetic, oncology, diagnostics, testing
NEO EPS (Earnings per Share)
NEO Revenue
Description: NEO NeoGenomics
NeoGenomics (NASDAQ:NEO) operates a national network of specialty diagnostic laboratories focused on oncology and genetic testing, serving oncologists, hospitals, and pharmaceutical sponsors. Its revenue model is driven by test volume growth, payer reimbursement rates, and contracts with pharmaceutical companies for companion diagnostics in clinical trials.
Key performance indicators show a compound annual revenue growth rate of roughly 15% over the past three years, with recent quarterly revenue exceeding $300 million and a gross margin consistently above 45%. Operating cash flow remains positive, supporting ongoing capital expenditures for laboratory automation and expansion of its molecular testing platform.
Strategic levers include expanding the test menu to cover emerging immuno‑oncology biomarkers, leveraging its proprietary bioinformatics pipeline to increase test turnaround speed, and deepening relationships with pharmaceutical partners for trial enrollment services. These initiatives aim to capture higher share of the growing $15 billion U.S. oncology diagnostics market.
Economic drivers affecting NeoGenomics are the rising incidence of cancer, increasing adoption of personalized medicine, and evolving payer policies that favor value‑based reimbursement for molecular diagnostics. Conversely, regulatory scrutiny and potential reimbursement cuts represent downside risks that the company mitigates through diversified payer mix and a focus on high‑margin, high‑complexity tests.
NEO Stock Overview
| Market Cap in USD | 966m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 1999-11-02 |
NEO Stock Ratings
| Growth Rating | -55.7% |
| Fundamental | 37.6% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -58.0% |
| Analyst Rating | 4.0 of 5 |
NEO Dividends
Currently no dividends paidNEO Growth Ratios
| Growth Correlation 3m | 18.6% |
| Growth Correlation 12m | -86.9% |
| Growth Correlation 5y | -65.1% |
| CAGR 5y | -4.36% |
| CAGR/Max DD 3y | -0.06 |
| CAGR/Mean DD 3y | -0.17 |
| Sharpe Ratio 12m | 0.14 |
| Alpha | 0.01 |
| Beta | 0.983 |
| Volatility | 79.85% |
| Current Volume | 3896.5k |
| Average Volume 20d | 2459.5k |
| Stop Loss | 7.5 (-7.5%) |
| Signal | 0.90 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-104.0m TTM) > 0 and > 6% of Revenue (6% = 41.4m TTM) |
| FCFTA -0.02 (>2.0%) and ΔFCFTA -0.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 42.43% (prev 46.84%; Δ -4.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 14.0m > Net Income -104.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.92 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (25.6m) change vs 12m ago 1.22% (target <= -2.0% for YES) |
| Gross Margin 43.91% (prev 42.64%; Δ 1.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.38% (prev 38.23%; Δ 7.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -20.57 (EBITDA TTM -48.5m / Interest Expense TTM 5.82m) >= 6 (WARN >= 3) |
Altman Z'' -0.85
| (A) 0.21 = (Total Current Assets 392.6m - Total Current Liabilities 100.1m) / Total Assets 1.39b |
| (B) -0.28 = Retained Earnings (Balance) -396.8m / Total Assets 1.39b |
| (C) -0.08 = EBIT TTM -119.6m / Avg Total Assets 1.52b |
| (D) -0.73 = Book Value of Equity -396.6m / Total Liabilities 539.9m |
| Total Rating: -0.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 37.61
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -2.97% = -1.48 |
| 3. FCF Margin -4.94% = -1.85 |
| 4. Debt/Equity 0.40 = 2.42 |
| 5. Debt/Ebitda -7.12 = -2.50 |
| 6. ROIC - WACC (= -15.83)% = -12.50 |
| 7. RoE -11.71% = -1.95 |
| 8. Rev. Trend 97.67% = 7.33 |
| 9. EPS Trend 23.03% = 1.15 |
What is the price of NEO shares?
Over the past week, the price has changed by +8.42%, over one month by +29.97%, over three months by +16.02% and over the past year by -50.21%.
Is NeoGenomics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NEO is around 6.55 USD . This means that NEO is currently overvalued and has a potential downside of -19.24%.
Is NEO a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NEO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.8 | 20.6% |
| Analysts Target Price | 9.8 | 20.6% |
| ValueRay Target Price | 7.2 | -11% |
Last update: 2025-09-11 04:45
NEO Fundamental Data Overview
CCE Cash And Equivalents = 163.7m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 222.2222
P/S = 1.402
P/B = 1.1889
P/EG = 3.02
Beta = 1.615
Revenue TTM = 689.2m USD
EBIT TTM = -119.6m USD
EBITDA TTM = -48.5m USD
Long Term Debt = 341.1m USD (from longTermDebt, last quarter)
Short Term Debt = 4.05m USD (from shortTermDebt, last quarter)
Debt = 345.1m USD (Calculated: Short Term 4.05m + Long Term 341.1m)
Net Debt = 257.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (966.3m + Debt 345.1m - CCE 163.7m)
Interest Coverage Ratio = -20.57 (Ebit TTM -119.6m / Interest Expense TTM 5.82m)
FCF Yield = -2.97% (FCF TTM -34.0m / Enterprise Value 1.15b)
FCF Margin = -4.94% (FCF TTM -34.0m / Revenue TTM 689.2m)
Net Margin = -15.10% (Net Income TTM -104.0m / Revenue TTM 689.2m)
Gross Margin = 43.91% ((Revenue TTM 689.2m - Cost of Revenue TTM 386.5m) / Revenue TTM)
Tobins Q-Ratio = -2.89 (set to none) (Enterprise Value 1.15b / Book Value Of Equity -396.6m)
Interest Expense / Debt = 0.27% (Interest Expense 933.0k / Debt 345.1m)
Taxrate = 21.0% (US default)
NOPAT = -119.6m (EBIT -119.6m, no tax applied on loss)
Current Ratio = 3.92 (Total Current Assets 392.6m / Total Current Liabilities 100.1m)
Debt / Equity = 0.40 (Debt 345.1m / last Quarter total Stockholder Equity 854.0m)
Debt / EBITDA = -7.12 (Net Debt 257.0m / EBITDA -48.5m)
Debt / FCF = -10.14 (Debt 345.1m / FCF TTM -34.0m)
Total Stockholder Equity = 888.2m (last 4 quarters mean)
RoA = -7.46% (Net Income -104.0m, Total Assets 1.39b )
RoE = -11.71% (Net Income TTM -104.0m / Total Stockholder Equity 888.2m)
RoCE = -9.73% (Ebit -119.6m / (Equity 888.2m + L.T.Debt 341.1m))
RoIC = -8.67% (NOPAT -119.6m / Invested Capital 1.38b)
WACC = 7.16% (E(966.3m)/V(1.31b) * Re(9.64%)) + (D(345.1m)/V(1.31b) * Rd(0.27%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 0.25%
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -34.0m)
EPS Correlation: 23.03 | EPS CAGR: 57.11% | SUE: 0.10 | # QB: 0
Revenue Correlation: 97.67 | Revenue CAGR: 13.25% | SUE: -0.28 | # QB: 0
Additional Sources for NEO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle